BACKGROUND: Young age and thiopurine therapy are risk factors for lymphoproliferative disease among patients with inflammatory bowel disease (IBD). AIMS: The aims of this study were to evaluate the prevalence of seropositivity for the Epstein-Barr virus (EBV) and human cytomegalovirus (CMV) among children and adolescents with IBD, to assess the viral load of EBV, CMV, and BK and JC polyomaviruses (BKV, JCV) in these patients, and to assess the influence of different therapeutic regimens on seroprevalence and viral load. METHODS: Children who had been followed in our center were tested for EBV, CMV, BKV, and JCV in a cross-sectional study. One hundred and six children were included who had Crohn's disease (68%), ulcerative colitis (29%), and unclassified IBD (3%). RESULTS: We found that 64% of patients were EBV seropositive. The proportion of EBV seropositive patients increased during childhood. Azathioprine therapy (p = 0.003) was associated with EBV seropositivity in a multiple logistic regression model, after adjusting for gender, age, and disease activity at determination. We found a significant association between the number of polymerase chain reaction copies and infliximab dose (p = 0.023). We did not find any significant association between CMV serology and CMV, BKV, or JCV viral load, or any other therapeutic regimen or clinical characteristics. CONCLUSIONS: Treatment with azathioprine appears to be a risk factor for early EBV seropositivity in children with IBD, and the infliximab dose was associated with a higher EBV viral load.

Department of Microbiology University Hospital Motol and 2nd Faculty of Medicine Charles University Prague Prague Czech Republic

Department of Pediatrics University Hospital Motol and 2nd Faculty of Medicine Charles University Prague 5 Uvalu 84 Prague 5 150 06 Czech Republic

000      

00000naa a2200000 a 4500

001      

bmc16010087

003      

CZ-PrNML

005      

20160413101457.0

007      

ta

008      

160408s2015 xxu f 000 0|eng||

009      

AR

024    7_

$a 10.1007/s10620-015-3764-z $2 doi

024    7_

$a 10.1007/s10620-015-3764-z $2 doi

035    __

$a (PubMed)26091801

040    __

$a ABA008 $b cze $d ABA008 $e AACR2

041    0_

$a eng

044    __

$a xxu

100    1_

$a Hradsky, Ondrej $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University in Prague, V Uvalu 84, Prague 5, 150 06, Czech Republic. ondrej.hradsky@lfmotol.cuni.cz.

245    10

$a Seroprevalence of Epstein-Barr Virus, Cytomegalovirus, and Polyomaviruses in Children with Inflammatory Bowel Disease / $c O. Hradsky, I. Copova, K. Zarubova, M. Durilova, J. Nevoral, M. Maminak, P. Hubacek, J. Bronsky,

520    9_

$a BACKGROUND: Young age and thiopurine therapy are risk factors for lymphoproliferative disease among patients with inflammatory bowel disease (IBD). AIMS: The aims of this study were to evaluate the prevalence of seropositivity for the Epstein-Barr virus (EBV) and human cytomegalovirus (CMV) among children and adolescents with IBD, to assess the viral load of EBV, CMV, and BK and JC polyomaviruses (BKV, JCV) in these patients, and to assess the influence of different therapeutic regimens on seroprevalence and viral load. METHODS: Children who had been followed in our center were tested for EBV, CMV, BKV, and JCV in a cross-sectional study. One hundred and six children were included who had Crohn's disease (68%), ulcerative colitis (29%), and unclassified IBD (3%). RESULTS: We found that 64% of patients were EBV seropositive. The proportion of EBV seropositive patients increased during childhood. Azathioprine therapy (p = 0.003) was associated with EBV seropositivity in a multiple logistic regression model, after adjusting for gender, age, and disease activity at determination. We found a significant association between the number of polymerase chain reaction copies and infliximab dose (p = 0.023). We did not find any significant association between CMV serology and CMV, BKV, or JCV viral load, or any other therapeutic regimen or clinical characteristics. CONCLUSIONS: Treatment with azathioprine appears to be a risk factor for early EBV seropositivity in children with IBD, and the infliximab dose was associated with a higher EBV viral load.

650    _2

$a mladiství $7 D000293

650    _2

$a věkové faktory $7 D000367

650    _2

$a azathioprin $x škodlivé účinky $7 D001379

650    _2

$a dítě $7 D002648

650    _2

$a předškolní dítě $7 D002675

650    _2

$a ulcerózní kolitida $x diagnóza $x farmakoterapie $x epidemiologie $x imunologie $7 D003093

650    _2

$a Crohnova nemoc $x diagnóza $x farmakoterapie $x epidemiologie $x imunologie $7 D003424

650    _2

$a průřezové studie $7 D003430

650    _2

$a cytomegalovirové infekce $x diagnóza $x epidemiologie $x imunologie $x virologie $7 D003586

650    _2

$a infekce virem Epsteina-Barrové $x diagnóza $x epidemiologie $x imunologie $x virologie $7 D020031

650    _2

$a ženské pohlaví $7 D005260

650    _2

$a lidé $7 D006801

650    _2

$a hostitel s imunodeficiencí $7 D016867

650    _2

$a imunosupresiva $x škodlivé účinky $7 D007166

650    _2

$a infliximab $x škodlivé účinky $7 D000069285

650    _2

$a logistické modely $7 D016015

650    _2

$a mužské pohlaví $7 D008297

650    _2

$a multivariační analýza $7 D015999

650    _2

$a odds ratio $7 D016017

650    _2

$a oportunní infekce $x diagnóza $x epidemiologie $x imunologie $x virologie $7 D009894

650    _2

$a polyomavirové infekce $x diagnóza $x epidemiologie $x imunologie $x virologie $7 D027601

650    _2

$a prevalence $7 D015995

650    _2

$a rizikové faktory $7 D012307

650    _2

$a séroepidemiologické studie $7 D016036

650    _2

$a sérologické testy $7 D012698

650    _2

$a virová nálož $7 D019562

651    _2

$a Česká republika $x epidemiologie $7 D018153

655    _2

$a časopisecké články $7 D016428

655    _2

$a práce podpořená grantem $7 D013485

700    1_

$a Copova, Ivana $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University in Prague, V Uvalu 84, Prague 5, 150 06, Czech Republic.

700    1_

$a Zarubova, Kristyna $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University in Prague, V Uvalu 84, Prague 5, 150 06, Czech Republic.

700    1_

$a Durilova, Marianna $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University in Prague, V Uvalu 84, Prague 5, 150 06, Czech Republic.

700    1_

$a Nevoral, Jiri $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University in Prague, V Uvalu 84, Prague 5, 150 06, Czech Republic.

700    1_

$a Maminak, Miroslav $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University in Prague, V Uvalu 84, Prague 5, 150 06, Czech Republic.

700    1_

$a Hubacek, Petr $u Department of Microbiology, University Hospital Motol and Second Faculty of Medicine, Charles University in Prague, Prague, Czech Republic.

700    1_

$a Bronsky, Jiri $u Department of Pediatrics, University Hospital Motol and Second Faculty of Medicine, Charles University in Prague, V Uvalu 84, Prague 5, 150 06, Czech Republic.

773    0_

$w MED00009570 $t Digestive diseases and sciences $x 1573-2568 $g Roč. 60, č. 11 (2015), s. 3399-407

856    41

$u https://pubmed.ncbi.nlm.nih.gov/26091801 $y Pubmed

910    __

$a ABA008 $b sig $c sign $y a $z 0

990    __

$a 20160408 $b ABA008

991    __

$a 20160413101540 $b ABA008

999    __

$a ok $b bmc $g 1113516 $s 934455

BAS    __

$a 3

BAS    __

$a PreBMC

BMC    __

$a 2015 $b 60 $c 11 $d 3399-407 $e 20150620 $i 1573-2568 $m Digestive diseases and sciences $n Dig Dis Sci $x MED00009570

LZP    __

$a Pubmed-20160408